Nicolaas M. J. Vermeulen

Irreversible enzyme inhibitors. CLXXV. Irreversible inhibition of purifed dihydrofolic reductase

Irreversible enzyme inhibitors. CLXVI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 2,4-diamino-5(3,4-dichlorophenyl)pyrimidine with 6 substituents and some factors in their cell wall transport.

Irreversible enzyme inhibitors. CLXXVII. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines. II.

Irreversible enzyme inhibitors. CLXXIV. Metabolism of 4-[p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)hydrocinnamido]-o-toluenesulfonyl fluoride (NSC-113423), and active-site-directed irreversible inhibitor of dihydrofolic reductase

Irreversible enzyme inhibitors. 133. Studies on differential irreversible inhibition of dihydrofolic reductase from three strains of L1210 leukemia, liver, spleen, and intestine of the mouse.

Irreversible enzyme inhibitors. CLXXIII. Cure of Walker 256 ascites by reversible and irreversible inhibitors of dihydrofolic reductase derived from 1-(substituted-phenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine

Irreversible enzyme inhibitors. CXXXIV. Effect of ring substitution on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonyl-phenylureido)phenoxymethyl]pyrimidine.

Irreversible enzyme inhibitors. CLX. Some factors in cell wall transport of active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines.

Irreversible enzyme inhibitors. CXXXVII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-(p-aminomethylphenoxymethyl)-2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine bearing a terminal sulfonyl fluoride.

Irreversible enzyme inhibitors. CLVII. Effect of bridge modification on the selective irreversible inhibition of dihydrofolic reductase from L1210 mouse leukemia and liver by 2,4-diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosultonyl-benzamidomethyl) phenozymethyl]pyrimidine. I.